Across TCGA pan-cancer cohorts, ZNF717 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ZNF717 data layer compared with 23 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher ZNF717 Mutation is associated with better overall survival. In most high-consensus cancer types, elevated ZNF717 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

UCEC, MESO, and SARC are the cancer types where ZNF717 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	OS	Median	II,III,IV	1.000	0.319	.007	32	view →
MESO	DFS	Median	II,III,IV	0.078	0.412	<.001	30	view →
SARC	DFS	Median	All	0.121	0.611	.041	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: ZNF717 tumor-vs-normal RNA expression · all ZNF717 data types